Major Win for Childhood Cancer Advocacy: UN Adopts GICC Target
Marty Makary: FDA Rejection Letters are Now Public
FDA Approves RYBREVANT FASPRO as the First Subcutaneous Amivantamab Option for EGFR-Mutated NSCLC
ASCO Joins One Voice Against Cancer’s Day of Action Urging Congress to Pass a Final Labor-HHS Funding Bill
Tom Powles: Another Step Towards Curing Bladder Cancer
Maryam Lustberg: From Phase 2 Promise to Phase 3 Proof in Neuropathy Prevention
David Steensma: Ajax Therapeutics Receives Orphan Drug Designation by FDA for AJ1-11095 for the Treatment of Myelofibrosis
FDA Awarded a National Priority Voucher to Teclistamab with Daratumumab for R/R Multiple Myeloma
ANCO’s Hematologic Malignancies Update 2026, held May 2–3, 2026, at the Hyatt Regency Monterey, will provide clinicians, nurses, nurse practitioners, and physician assistants with the latest advances in the treatment of hematologic malignancies.
The two-day meeting features expert-led sessions on clinically relevant topics to support evidence-based practice in hematology and oncology.